Muscarisan Combi (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin hydrochloride and solifenacin succinate, the active ingredients in Muscarisan Combi, are an alpha‑1 adrenergic antagonist and a muscarinic M3 antagonist presented as an oral tablet for oral use. They are indicated for the management of urinary symptoms associated with benign prostatic hyperplasia and overactive bladder in adult males and females.

GNH USA supplies Muscarisan Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Muscarisan Combi acts on the lower urinary tract to relieve both obstructive and storage symptoms. - Benign prostatic hyperplasia (BPH): improves urine flow and reduces bladder outlet obstruction. - Overactive bladder (OAB): decreases urgency, frequency and nocturia. - Mixed urinary symptoms: provides combined relief of voiding and storage disturbances.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially on standing. - Dry mouth: reduced salivation leading to throat discomfort. - Constipation: slowed gastrointestinal motility. - Headache: transient cranial pain. - Blurred vision: temporary visual disturbances. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Priapism: prolonged painful erection requiring urgent care. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Urinary retention: inability to void, may need catheterisation. - QT prolongation: cardiac rhythm disturbance, monitor in at‑risk patients.

Before initiating Muscarisan Combi, consider the following precautions: - Renal impairment: assess kidney function and adjust therapy if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor blood pressure and heart rate. - Elderly patients: increased risk of falls and orthostatic hypotension. - Concomitant anticholinergic drugs: may enhance dry‑mouth and constipation. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Muscarisan Combi may interact with several medicines; review patient medication lists. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may raise solifenacin levels and increase side‑effects. - CYP2D6 inhibitors: can elevate tamsulosin concentrations, enhancing hypotension risk. - Other alpha‑blockers: additive blood‑pressure lowering effect. Moderate Interactions (Monitor Closely): - Diuretics: may potentiate orthostatic hypotension. - Additional anticholinergics: increase risk of dry mouth and constipation. - Beta‑blockers: possible additive cardiovascular effects.